Mark A. Yondola

TL;DR: The construction of a novel immunogen comprising the conserved influenza HA stalk domain and lacking the globular head is described, which shows that vaccination of mice with a headless HA confers protection to these animals against a lethal influenza virus challenge, and predicts that a single immunization with aHeadless HA vaccine will offer effective protection through several influenza epidemics.

TL;DR: Both strategies showed efficacy in reducing viral loads after an influenza virus challenge in the ferret model support the development of vaccines stimulating stalk-specific antibody responses.

TL;DR: The data suggest that budding-competent neuraminidase proteins possess an as-yet-unidentified means of counteracting the antiviral restriction factor tetherin and identify a novel way in which the influenza virus neuraminidsase can contribute to virus release.

TL;DR: It is demonstrated that local administration significantly decreases the amount of broadly neutralizing monoclonal antibody required for protection against influenza, which highlights the potential use of MAbs as a therapeutic agent for influenza-associated disease.

TL;DR: It is shown that the presence of aspartate at residue 286 liberates NA from tetherin-dependent restriction upon exit from the ER compartment thus preventing restriction at the plasma membrane.